---
input_text: 'A telephonic mindfulness-based intervention for persons with sickle cell
  disease: study protocol for a randomized controlled trial. BACKGROUND: One of the
  most difficult symptoms for persons with sickle cell disease (SCD) to manage is
  chronic pain. Chronic pain impacts approximately one-third of persons with SCD and
  is associated with increased pain intensity, pain behavior, and frequency and duration
  of hospital visits. A promising category of nonpharmacological interventions for
  managing both physical and affective components of pain are mindfulness-based interventions
  (MBIs). METHODS/DESIGN: The primary aim of this study is to conduct a randomized
  controlled study to evaluate the acceptability and feasibility, as well as to determine
  the preliminary efficacy, of a telephonic MBI for adults with SCD who have chronic
  pain. We will enroll 60 adult patients with SCD and chronic pain at an outpatient
  comprehensive SCD center in the southeastern United States. Patients will be randomized
  to either an MBI or a wait-listed control group. The MBI group will complete a six-session
  (60 minutes), telephonically delivered, group-based MBI program. The feasibility,
  acceptability, and efficacy of the MBI regarding pain catastrophizing will be assessed
  by administering questionnaires at baseline and weeks 1, 3, and 6. In addition,
  ten randomly selected MBI participants will complete semistructured interviews to
  help determine intervention acceptability. DISCUSSION: In this study protocol, we
  report detailed methods of the randomized controlled trial. Findings of this study
  will be useful to determine the acceptability, feasibility, and efficacy of an MBI
  for persons with SCD and chronic pain. TRIAL REGISTRATION: ClinicalTrials.gov identifier:
  NCT02394587 . Registered on 9 February 2015.'
raw_completion_output: |-
  primary_disease: sickle cell disease
  medical_actions: telephonic mindfulness-based intervention; randomized controlled trial; administering questionnaires; semistructured interviews
  symptoms: chronic pain; pain catastrophizing; increased pain intensity; pain behavior
  chemicals: 
  action_annotation_relationships: telephonic mindfulness-based intervention TREATS chronic pain IN sickle cell disease; administering questionnaires ASSESSES pain catastrophizing IN sickle cell disease; semistructured interviews ASSESS acceptability OF telephonic mindfulness-based intervention IN sickle cell disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  semistructured interviews ASSESS acceptability OF telephonic mindfulness-based intervention IN sickle cell disease

  ===

extracted_object:
  primary_disease: MONDO:0011382
  medical_actions:
    - telephonic mindfulness-based intervention
    - randomized controlled trial
    - administering questionnaires
    - semistructured interviews
  symptoms:
    - HP:0012532
    - pain catastrophizing
    - increased pain intensity
    - pain behavior
  action_annotation_relationships:
    - subject: <telephonic mindfulness-based intervention>
      predicate: <TREATS>
      object: <chronic pain>
      qualifier: <sickle cell disease>
      subject_extension: <telephonic mindfulness-based intervention>
    - subject: <administering questionnaires>
      predicate: <ASSESSES>
      object: <pain catastrophizing>
      qualifier: <sickle cell disease>
      subject_qualifier: <None>
      object_qualifier: <None>
      subject_extension: <None>
      object_extension: <None>
    - subject: <semistructured interviews>
      predicate: <ASSESS>
      object: <acceptability>
      qualifier: <sickle cell disease>
      subject_qualifier: <NA>
      object_qualifier: <NA>
      subject_extension: <telephonic mindfulness-based intervention>
      object_extension: <NA>
named_entities:
  - id: MONDO:0011382
    label: sickle cell disease
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:81579
    label: erythropoietin
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:35480
    label: analgesics
  - id: CHEBI:33281
    label: antibiotics
  - id: MAXO:0001077
    label: Splenectomy
  - id: MAXO:0000756
    label: Blood transfusion
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: HP:0001297
    label: Stroke
  - id: HP:0002863
    label: Myelodysplastic syndrome
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:82594
    label: Ferritin
  - id: MONDO:0000984
    label: thalassemia
  - id: MONDO:0018881
    label: myelodysplastic syndrome
  - id: HP:0002140
    label: Ischemic Stroke
  - id: MONDO:0005380
    label: avascular necrosis
  - id: MAXO:0009047
    label: total hip replacement
  - id: HP:0010885
    label: avascular necrosis
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:9168
    label: sirolimus
  - id: CHEBI:8764
    label: mycophenolate mofetil
  - id: HP:0012531
    label: Pain
  - id: MAXO:0000515
    label: Extracorporeal life support
  - id: HP:0001708
    label: Right ventricular failure
  - id: HP:0033515
    label: opioid dependence
  - id: MONDO:0005632
    label: Acute chest syndrome in sickle cell disease
  - id: HP:0001945
    label: fever
  - id: HP:0001878
    label: Hemolytic anemia
  - id: CHEBI:6121
    label: ketamine
  - id: CHEBI:17303
    label: morphine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0031274
    label: hypovolemic shock
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: arginine
  - id: CHEBI:18211
    label: citrulline
  - id: CHEBI:3638
    label: chloroquine
  - id: CHEBI:50733
    label: nutritional supplements
  - id: MONDO:0005570
    label: Blood disorders
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0100626
    label: end-stage liver disease
  - id: MONDO:0016363
    label: Iron overload diseases
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0010203
    label: echocardiography
  - id: HP:0002870
    label: obstructive sleep apnoea (OSA)
  - id: HP:0000520
    label: Proptosis
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000058
    label: pharmacological treatment
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: HP:0002878
    label: Acute respiratory failure
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: CHEBI:35457
    label: angiotensin-converting enzyme inhibitor
  - id: MAXO:0000652
    label: angiotensin-converting enzyme inhibitor therapy
  - id: HP:0000112
    label: kidney disease
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0000827
    label: serum ferritin measurement
  - id: HP:0001875
    label: neutropenia
  - id: CHEBI:4356
    label: <desferrioxamine (DFO)
  - id: CHEBI:17941
    label: deferiprone (DFP)
  - id: CHEBI:49005
    label: deferasirox (DFX)
  - id: CHEBI:38157
    label: iron chelators
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:9144
    label: silymarin
  - id: MAXO:0000750
    label: conditioning regimens (fludarabine-thiotepa-treosulfan, busulfan-cyclophosphamide)
  - id: CHEBI:82557
    label: treosulfan
  - id: HP:0100602
    label: preeclampsia
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: CHEBI:50858
    label: corticosteroids
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
